Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has today announced that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of EarlyCDT-Lung in Israel.
On an age standardised basis, Israel’s lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. Lung cancer is responsible for more cancer-related deaths than any other cancer in Israel.1
Dr Adam M Hill, CEO of Oncimmune Holdings plc commented:
“We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel.”
Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. The company also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. ONC is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body’s natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. It partners with leading developers and distributors to make our technology available globally.
